These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12811813)

  • 1. Epstein-Barr virus: induction and control of cell transformation.
    Dolcetti R; Masucci MG
    J Cell Physiol; 2003 Aug; 196(2):207-18. PubMed ID: 12811813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.
    Masucci MG
    Oncogene; 2004 Mar; 23(11):2107-15. PubMed ID: 15021898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
    Beck Z; Illés A; Keresztes K; Bessenyei B; Szöllosi Z; Kis A; Oláh E
    Orv Hetil; 2006 Aug; 147(33):1539-44. PubMed ID: 17037676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
    Dantuma NP; Masucci MG
    Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent and lytic Epstein-Barr virus replication strategies.
    Tsurumi T; Fujita M; Kudoh A
    Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions.
    Klein E; Kis LL; Klein G
    Oncogene; 2007 Feb; 26(9):1297-305. PubMed ID: 17322915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of EBV encoded BARF1 gene on malignant transformation of human epithelial cell line HBE].
    Song LB; Zen MS; Zhang L; Li MZ; Liao WT; Zheng ML; Wang HM; Zeng YX
    Ai Zheng; 2004 Nov; 23(11 Suppl):1361-4. PubMed ID: 15566637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide transcription program and expression of the Rta responsive gene of Epstein-Barr virus.
    Lu CC; Jeng YY; Tsai CH; Liu MY; Yeh SW; Hsu TY; Chen MR
    Virology; 2006 Feb; 345(2):358-72. PubMed ID: 16298410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2.
    Sheng W; Decaussin G; Sumner S; Ooka T
    Oncogene; 2001 Mar; 20(10):1176-85. PubMed ID: 11313861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human T cell immune response to Epstein-Barr virus.
    Landais E; Saulquin X; Houssaint E
    Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
    Niller HH; Wolf H; Minarovits J
    Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells.
    Li HM; Zhuang ZH; Wang Q; Pang JC; Wang XH; Wong HL; Feng HC; Jin DY; Ling MT; Wong YC; Eliopoulos AG; Young LS; Huang DP; Tsao SW
    Oncogene; 2004 May; 23(25):4488-94. PubMed ID: 15064751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms.
    Deyrup AT
    Hum Pathol; 2008 Apr; 39(4):473-83. PubMed ID: 18342658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Epstein-Barr virus replication by small interfering RNA targeting the Epstein-Barr virus protease gene.
    Larrat S; Morand P; Bas A; Vigne S; Crance JM; Boyer V; Nicod S; Grossi L; Buisson M; Burmeister WP; Seigneurin JM; Germi R
    Antivir Ther; 2009; 14(5):655-62. PubMed ID: 19704168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human gamma-herpesviruses: a review of 2 divergent paths to oncogenesis.
    Hardie DR
    Transfus Apher Sci; 2010 Apr; 42(2):177-83. PubMed ID: 20100669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.